{"ticker": {"uuid": "e3535c93-577a-4442-9726-fb16765063e2", "symbol": "XBIT", "name": "XBiotech Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading Continues - IPO Entry Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPUFpPWWo4a1J6Rm1wY0RRWFlaT05tWXBuTV9HQjRpTVFVdXpQM3k0bHRObHAtSE0zYUFQSTlRdHFrMThZV0I1THZfaVVEdXh3bWlwb2U3OVJGZEYyRFExN21YUjlnTkl4ejVla0JNaUdJYmpSOFRmQUw0Z2t0VlEzdGlhQmIwS3pzaExuSGhfRGFrd2hmME9Gb0pTa2RMaUlkOHVlcTlweV9LUUF2Slgw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T17:41:02+00:00", "published_display": "12 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18 - Pairs Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNUHJtQkhMQzJub3otVWw2M3M4dmlhNVNoaklnOGxrd05fZ3drTGRrZUZBTmdMTUtlVThQN2FodzJYYlYxLWlwaW1pWWI0WUUtUmRXc0tVRE9ZQmxXYVJkaDZVWklST1E1VFpTZjdOa29PbFV2NjF0b0FyLXBCVkNpNHI1bFUxelAwZzFpc2N0eE5GM00zZHV3Z29PRWFMNm5KMmFNY1dRcEZnTmpwX0dB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T00:36:03+00:00", "published_display": "10 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech focuses on antibody pipeline as biotech sector evolves", "summary": "XBiotech Inc. is advancing its antibody-based therapies in the competitive biotech sector, concentrating on specific inflammatory and oncology indications to optimize capital and address significant patient needs. The company's strategy involves developing human-derived antibodie", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xbiotech-focuses-on-antibody-pipeline-as-biotech-sector-evolves/69725009", "source_name": "Ad Hoc News", "published_at": "2026-07-08T17:48:00", "published_display": "08 Jul 2026 17:48", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in XBiotech, Inc. Stocks", "summary": "This article lists ETFs that invest in XBiotech, Inc. stocks, providing details such as market value, weight, issuer, management style, and expense ratio for each ETF. It highlights two specific ETFs: Bridgeway Omni Small-Cap Value ETF (BSVO) and Avantis U.S. Small Cap Value ETF ", "url": "https://www.tradingview.com/symbols/BX-4XB/etfs/", "source_name": "TradingView", "published_at": "2026-07-05T11:40:46", "published_display": "05 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (SWB:4XB)", "summary": "The article provides an overview of XBiotech, Inc.'s financial actuals and estimates, including income statement, balance sheet, and cash flow data, available on TradingView. It also addresses frequently asked questions about the company's stock ticker (4XB on SWB), historical st", "url": "https://www.tradingview.com/symbols/SWB-4XB/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-28T20:09:18", "published_display": "28 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (MUN:4XB)", "summary": "This article provides an overview of XBiotech, Inc. (MUN:4XB) financial data and analyst estimates available on TradingView. It includes information on the company's income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with e", "url": "https://www.tradingview.com/symbols/MUN-4XB/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T11:10:19", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of XBiotech Inc. \u2013 NASDAQ:XBIT", "summary": "This page provides access to the \"Price to book forward\" financial metric for XBiotech Inc. (NASDAQ:XBIT) on TradingView. It specifies the data period, value, and change, noting that the content is made by humans and supported by various financial data providers. The main focus i", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:09:46", "published_display": "27 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (FWB:4XB)", "summary": "This TradingView page provides actuals and estimates for XBiotech, Inc. (FWB:4XB), allowing users to explore reported financial data and analyst estimates across various financial statements. It includes information on the company's stock ticker, all-time high and low prices, net", "url": "https://www.tradingview.com/symbols/FWB-4XB/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T03:40:34", "published_display": "27 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (LS:A14QF1)", "summary": "This article provides financial actuals and estimates for XBiotech, Inc. (A14QF1) on TradingView, detailing its current stock price, market capitalization, and historical performance. It also includes frequently asked questions about the company's stock, financials, and how to in", "url": "https://www.tradingview.com/symbols/LS-A14QF1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:34", "published_display": "26 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT)", "summary": "This article provides an overview of XBiotech Inc. (NASDAQ:XBIT) financial actuals and estimates, including its current stock price, historical performance, market capitalization, and volatility. It also touches upon frequently asked questions regarding its stock ticker, net inco", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:39:17", "published_display": "26 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of XBiotech Inc. \u2013 NASDAQ:XBIT", "summary": "This article provides financial information for XBiotech Inc. (NASDAQ: XBIT), specifically focusing on its price-to-sales forward metric. The content highlights that XBiotech is a health technology and biotechnology company listed on the Nasdaq Stock Market, and it presents an ov", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:17", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (BOATS:XBIT)", "summary": "This article provides an overview of XBiotech Inc.'s financial actuals and estimates available on TradingView, covering income statements, balance sheets, and cash flow. It also includes frequently asked questions about the company's stock ticker, historical prices, net income, a", "url": "https://www.tradingview.com/symbols/BOATS-XBIT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:12", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc. (XBIT) Nears Key Support After 2.5% Decline - Advance Decline Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNODhBUV9VU3VfX0E5OXoxOGxxZElXcXF2ODVUdWh2Ml9FdFBNb3B5cGVPd2htZ3F0RUQ5NjZiOTY5T2hRZ0FyVFZTeUNoQjlfcE91TWNCaUNnSjFwTmd1ZkVsblFZaGlZSDd2ZUV6UHVPN0FzaHRPZ3IxVVVJN2FKZ3lPZEJjeGRHR1cybTcyUjV4U2NqcXJHQ0ZHRTk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Institutional Confidence", "summary": "The article provides an overview of XBiotech Inc.'s (XBIT) institutional confidence score and shareholding details. XBIT has a current institutional shareholding score of 3.00, ranking 193rd in its industry, with a 12.25% institutional shareholding proportion showing a 42.58% qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T14:39:42", "published_display": "18 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of XBiotech Inc's (XBIT) financial health, noting its strong financial status and high operating efficiency with a current financial score of 6.88. The analysis covers profitability and balance sheet aspects, though specific financial data for se", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:34", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for XBiotech Inc (XBIT), highlighting that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company for FY2023. It shows current stock performance information for XBI", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:13", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for XBiotech Inc (XBIT) from TradingKey. It notes that no earnings forecast score is currently available for XBiotech Inc., contrasting with the Biotechnology & Medical Research industry's average score of 8.15. The report also indicates", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:42", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for XBiotech Inc (XBIT), highlighting its current valuation score and P/E ratio within the Biotechnology & Medical Research industry. It notes that key P/B, P/S, and P/CF data have not been disclosed by the company. The analysis also inc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:24", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of XBiotech Inc (XBIT), focusing on its price momentum, support and resistance levels, and key technical indicators. It notes that XBIT's current price momentum score is 5.68, ranking 310 out of 388 in its industry, and the stock is trad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/technical", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:53", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of XBiotech Inc (XBIT), listing both major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities. Key shareholde", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T15:09:12", "published_display": "17 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis", "summary": "XBiotech Inc. has announced the launch of a Phase II clinical trial (V-SPINE) for vilamakitug, a potential treatment for active axial spondyloarthritis, after its Investigational New Drug application cleared the FDA's 30-day review. This study will evaluate the efficacy and safet", "url": "https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-for-the-treatment-of-active-axial-spondyloarthritis/2365646", "source_name": "The Manila Times", "published_at": "2026-06-17T10:40:21", "published_display": "17 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of XBiotech Inc's (XBIT) dividend and stock split history. It notes that no dividends have been distributed over the past five years and no stock splits have been recorded. The page displays the current stock price, market cap, and links to other", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:09:13", "published_display": "17 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Receives Authorization for V-SPINE Trial", "summary": "XBiotech has received FDA authorization to begin its V-SPINE trial, which will enroll 150 patients with active axial spondyloarthritis to evaluate the efficacy of Vilamakitug (XP2001 or Natrunix). This IgG4 monoclonal antibody targets IL-1\u03b1, aiming to reduce structural damage and", "url": "https://intellectia.ai/news/stock/xbiotech-receives-authorization-for-vspine-trial", "source_name": "Intellectia AI", "published_at": "2026-06-16T05:39:22", "published_display": "16 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondyloarthritis", "summary": "The FDA has cleared XBiotech Inc. to proceed with its Phase II V-SPINE trial of vilamakitug for active axial spondyloarthritis, marking a restart of the company's rheumatology program. This regulatory approval allows XBiotech to begin enrolling patients in the U.S. for the random", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xbiotech-inc-stock-us9840001002-fda-clears-phase-ii-v-spine-trial-for/69547716", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T01:09:26", "published_display": "16 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech clears FDA review for axial spondyloarthritis study", "summary": "XBiotech Inc. has announced that its Investigational New Drug application for the V-SPINE study successfully completed the FDA's 30-day review period without a clinical hold, allowing the company to proceed with patient enrollment in the U.S. for its Phase II axial spondyloarthri", "url": "https://www.investing.com/news/company-news/xbiotech-clears-fda-review-for-axial-spondyloarthritis-study-93CH-4742224", "source_name": "Investing.com", "published_at": "2026-06-15T13:09:26", "published_display": "15 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA review lets XBiotech resume rheumatology with axial spondyloarthritis trial", "summary": "XBiotech (NASDAQ: XBIT) announced FDA clearance for its Phase II V-SPINE trial of vilamakitug for active axial spondyloarthritis, allowing U.S. patient enrollment. The IND application completed its 30-day review without clinical hold, marking the resumption of XBiotech\u2019s rheumato", "url": "https://www.stocktitan.net/news/XBIT/x-biotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-erzx8m4p9w29.html", "source_name": "Stock Titan", "published_at": "2026-06-15T13:09:26", "published_display": "15 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIT - XBiotech Inc Dividends", "summary": "This article provides a detailed financial overview of XBiotech Inc (XBIT), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists dividend information such as the ex-dividend date (July 15, 2021) and performance metrics ", "url": "https://finviz.com/stock?t=XBIT&ta=1&p=d&ty=dv", "source_name": "Finviz", "published_at": "2026-06-03T20:41:05", "published_display": "03 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update", "summary": "XBiotech Inc. (XBIT) shares traded sideways on Nasdaq on June 2, 2026, as the Austin-based biotech company awaits its next earnings update. With no new company filings or press releases on the day, investor expectations are still shaped by results reported in late 2024. The compa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xbiotech-inc-stock-us9840001002-shares-little-changed-as-investors/69471161", "source_name": "Ad Hoc News", "published_at": "2026-06-02T13:39:03", "published_display": "02 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech: Q1 Earnings Snapshot", "summary": "XBiotech Inc. (XBIT) reported a first-quarter loss of $5.5 million, translating to 18 cents per share. This financial snapshot was generated using data from Zacks Investment Research.", "url": "https://www.barchart.com/story/news/1939735/xbiotech-q1-earnings-snapshot", "source_name": "Barchart.com", "published_at": "2026-05-29T06:41:20", "published_display": "29 May 2026 06:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xbiotech (XBIT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBOdkRCMEs4YTdnTm8yeFNNeG15NmltZU5hQjROTXl3T0tSMnBINUMySTlDUW4zZnNBTG8yUUQ5S3lLajhuRXNGTW9VcWliNzE1Zy1j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:03:39+00:00", "published_display": "24 Apr 2025 23:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First look: XBiotech to expand Austin HQ with more offices, state-of-the-art R&D facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPMkkycTBWZFdtVk1KREhCZUtaSXNDU3pTWDZoRlQ3bEg1bnZVWXpaT0E2Q1ZUMVBZWXBXa21sWkRlWkdEdWpqSVpUZzllbEcyNjVscFd1Y1J3ZjNZR1VfSlc0SlFybUZBLUpSVnJRZF9uRWE3c3hGeVdMUGNPQloxaTItaEx4VS1qS093ZjlWNXp3Vkl4dDBmLUJR?oc=5", "source_name": "The Business Journals", "published_at": "2020-12-23T08:00:00+00:00", "published_display": "23 Dec 2020 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbiotech Stock Price Forecast. Should You Buy XBIT?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE9CbDR0UnNTZUtlR1R5N0F6T2tuUUxuNlN1SXN0eVFKdkNac0RxSTJSMERuUEVIdlhYTVhnN3g4MXN5a21HS2RZQQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-02T17:57:50+00:00", "published_display": "02 Dec 2020 17:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janssen to Acquire Investigational Bermekimab from XBiotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbnJZM3pMelp6endYNzFpMDl0RnVvTDRZQmVwQTZyMkZIeTVQMWRac2ptUzc1ZHRnTlFDYjV4OHBhUS1WTXpzZ2ZNSW5aZW5ydDNueUNrYnZORjdRa2NLXzNfbDg2bG43Vk80SFB0ZUdzODc0NkpHaVRyWnJDVDVzTFUtb1pkcWFPQ1ZYRHBnM1huVmhoN3RVVXVpblE4RTNubUhwLVctTTZxa1FBaHc0SjJYa2lNdw?oc=5", "source_name": "PR Newswire", "published_at": "2019-12-07T08:00:00+00:00", "published_display": "07 Dec 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of XBiotech Inc. (NASDAQ:XBIT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE4zU1RVbGkyZmNteE9telYzN3E4ZkV3Q1Q2Y2JBN1F5UFZfRHFBSjI3dzJGNjdFNFZ4TEtUWk9ZWWJwZWNOVnQwQXJIaEl5WTk3SmtiSWxVYXNsUUgwTlJSeVZnWmdPYk1nenM0?oc=5", "source_name": "TradingView", "published_at": "2018-02-09T18:07:45+00:00", "published_display": "09 Feb 2018 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIT Stock Price and Chart \u2014 NASDAQ:XBIT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5jaExkNWJjTzU0OEhNOTNhWWFlTEdkRXlKN0V0bHR0eUg2bC1vbDdSZ2drcU1HM2IwTmRDaFpQUldTLXpKNFVVNzgySGtyZTZsRGlWbi1iNklwR0xn?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T05:24:49+00:00", "published_display": "21 Jul 2017 05:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech (XBIT) Stock Price, News & Analysis $XBIT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1wcXZqOWgzTFZYSVBGYVJmbm8zUXZWY0YwUjNlSWNsRkF2SnNEcFJNRU5aTUs3Z3dYZ2d0a0hKaUp6RnhxaU9ONjBpTEFxNkpnTy1fV1dNYURJUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-14T04:32:11+00:00", "published_display": "14 Aug 2016 04:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIT: XBiotech Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFBNZ1dBZkxSRE5jMmhab05oNHBDdUR2UlBrcGxUZ0o1U3B3VUh2QTI5N1VkTjhNS3l3aTh2T0tTVC1FZHk0Zy1jVlJR?oc=5", "source_name": "Stocktwits", "published_at": "2015-11-24T03:16:14+00:00", "published_display": "24 Nov 2015 03:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading Continues - IPO Entry Watch", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPUFpPWWo4a1J6Rm1wY0RRWFlaT05tWXBuTV9HQjRpTVFVdXpQM3k0bHRObHAtSE0zYUFQSTlRdHFrMThZV0I1THZfaVVEdXh3bWlwb2U3OVJGZEYyRFExN21YUjlnTkl4ejVla0JNaUdJYmpSOFRmQUw0Z2t0VlEzdGlhQmIwS3pzaExuSGhfRGFrd2hmME9Gb0pTa2RMaUlkOHVlcTlweV9LUUF2Slgw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-12T17:41:02+00:00", "published_display": "12 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18 - Pairs Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNUHJtQkhMQzJub3otVWw2M3M4dmlhNVNoaklnOGxrd05fZ3drTGRrZUZBTmdMTUtlVThQN2FodzJYYlYxLWlwaW1pWWI0WUUtUmRXc0tVRE9ZQmxXYVJkaDZVWklST1E1VFpTZjdOa29PbFV2NjF0b0FyLXBCVkNpNHI1bFUxelAwZzFpc2N0eE5GM00zZHV3Z29PRWFMNm5KMmFNY1dRcEZnTmpwX0dB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-10T00:36:03+00:00", "published_display": "10 Jul 2026 00:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech focuses on antibody pipeline as biotech sector evolves", "summary": "XBiotech Inc. is advancing its antibody-based therapies in the competitive biotech sector, concentrating on specific inflammatory and oncology indications to optimize capital and address significant patient needs. The company's strategy involves developing human-derived antibodie", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xbiotech-focuses-on-antibody-pipeline-as-biotech-sector-evolves/69725009", "source_name": "Ad Hoc News", "published_at": "2026-07-08T17:48:00", "published_display": "08 Jul 2026 17:48", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in XBiotech, Inc. Stocks", "summary": "This article lists ETFs that invest in XBiotech, Inc. stocks, providing details such as market value, weight, issuer, management style, and expense ratio for each ETF. It highlights two specific ETFs: Bridgeway Omni Small-Cap Value ETF (BSVO) and Avantis U.S. Small Cap Value ETF ", "url": "https://www.tradingview.com/symbols/BX-4XB/etfs/", "source_name": "TradingView", "published_at": "2026-07-05T11:40:46", "published_display": "05 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (SWB:4XB)", "summary": "The article provides an overview of XBiotech, Inc.'s financial actuals and estimates, including income statement, balance sheet, and cash flow data, available on TradingView. It also addresses frequently asked questions about the company's stock ticker (4XB on SWB), historical st", "url": "https://www.tradingview.com/symbols/SWB-4XB/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-28T20:09:18", "published_display": "28 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (MUN:4XB)", "summary": "This article provides an overview of XBiotech, Inc. (MUN:4XB) financial data and analyst estimates available on TradingView. It includes information on the company's income statement, balance sheet, cash flow, and valuation metrics, allowing users to compare actual results with e", "url": "https://www.tradingview.com/symbols/MUN-4XB/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T11:10:19", "published_display": "27 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of XBiotech Inc. \u2013 NASDAQ:XBIT", "summary": "This page provides access to the \"Price to book forward\" financial metric for XBiotech Inc. (NASDAQ:XBIT) on TradingView. It specifies the data period, value, and change, noting that the content is made by humans and supported by various financial data providers. The main focus i", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:09:46", "published_display": "27 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (FWB:4XB)", "summary": "This TradingView page provides actuals and estimates for XBiotech, Inc. (FWB:4XB), allowing users to explore reported financial data and analyst estimates across various financial statements. It includes information on the company's stock ticker, all-time high and low prices, net", "url": "https://www.tradingview.com/symbols/FWB-4XB/forecast-actuals-and-estimates/?category=income_statement", "source_name": "TradingView", "published_at": "2026-06-27T03:40:34", "published_display": "27 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (LS:A14QF1)", "summary": "This article provides financial actuals and estimates for XBiotech, Inc. (A14QF1) on TradingView, detailing its current stock price, market capitalization, and historical performance. It also includes frequently asked questions about the company's stock, financials, and how to in", "url": "https://www.tradingview.com/symbols/LS-A14QF1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T19:40:34", "published_display": "26 Jun 2026 19:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT)", "summary": "This article provides an overview of XBiotech Inc. (NASDAQ:XBIT) financial actuals and estimates, including its current stock price, historical performance, market capitalization, and volatility. It also touches upon frequently asked questions regarding its stock ticker, net inco", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:39:17", "published_display": "26 Jun 2026 14:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of XBiotech Inc. \u2013 NASDAQ:XBIT", "summary": "This article provides financial information for XBiotech Inc. (NASDAQ: XBIT), specifically focusing on its price-to-sales forward metric. The content highlights that XBiotech is a health technology and biotechnology company listed on the Nasdaq Stock Market, and it presents an ov", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T11:39:17", "published_display": "26 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech, Inc. Actuals & Estimates (BOATS:XBIT)", "summary": "This article provides an overview of XBiotech Inc.'s financial actuals and estimates available on TradingView, covering income statements, balance sheets, and cash flow. It also includes frequently asked questions about the company's stock ticker, historical prices, net income, a", "url": "https://www.tradingview.com/symbols/BOATS-XBIT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:12", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc. (XBIT) Nears Key Support After 2.5% Decline - Advance Decline Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNODhBUV9VU3VfX0E5OXoxOGxxZElXcXF2ODVUdWh2Ml9FdFBNb3B5cGVPd2htZ3F0RUQ5NjZiOTY5T2hRZ0FyVFZTeUNoQjlfcE91TWNCaUNnSjFwTmd1ZkVsblFZaGlZSDd2ZUV6UHVPN0FzaHRPZ3IxVVVJN2FKZ3lPZEJjeGRHR1cybTcyUjV4U2NqcXJHQ0ZHRTk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-20T07:00:00+00:00", "published_display": "20 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Institutional Confidence", "summary": "The article provides an overview of XBiotech Inc.'s (XBIT) institutional confidence score and shareholding details. XBIT has a current institutional shareholding score of 3.00, ranking 193rd in its industry, with a 12.25% institutional shareholding proportion showing a 42.58% qua", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T14:39:42", "published_display": "18 Jun 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of XBiotech Inc's (XBIT) financial health, noting its strong financial status and high operating efficiency with a current financial score of 6.88. The analysis covers profitability and balance sheet aspects, though specific financial data for se", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T07:10:34", "published_display": "18 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for XBiotech Inc (XBIT), highlighting that relevant data for business segments and regional revenue contribution have not yet been disclosed by the company for FY2023. It shows current stock performance information for XBI", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:13", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for XBiotech Inc (XBIT) from TradingKey. It notes that no earnings forecast score is currently available for XBiotech Inc., contrasting with the Biotechnology & Medical Research industry's average score of 8.15. The report also indicates", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:42", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for XBiotech Inc (XBIT), highlighting its current valuation score and P/E ratio within the Biotechnology & Medical Research industry. It notes that key P/B, P/S, and P/CF data have not been disclosed by the company. The analysis also inc", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:24", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of XBiotech Inc (XBIT), focusing on its price momentum, support and resistance levels, and key technical indicators. It notes that XBIT's current price momentum score is 5.68, ranking 310 out of 388 in its industry, and the stock is trad", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/technical", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:53", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of XBiotech Inc (XBIT), listing both major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding trends over several quarters, and recent shareholder activities. Key shareholde", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T15:09:12", "published_display": "17 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis", "summary": "XBiotech Inc. has announced the launch of a Phase II clinical trial (V-SPINE) for vilamakitug, a potential treatment for active axial spondyloarthritis, after its Investigational New Drug application cleared the FDA's 30-day review. This study will evaluate the efficacy and safet", "url": "https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-for-the-treatment-of-active-axial-spondyloarthritis/2365646", "source_name": "The Manila Times", "published_at": "2026-06-17T10:40:21", "published_display": "17 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of XBiotech Inc's (XBIT) dividend and stock split history. It notes that no dividends have been distributed over the past five years and no stock splits have been recorded. The page displays the current stock price, market cap, and links to other", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbit/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:09:13", "published_display": "17 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Receives Authorization for V-SPINE Trial", "summary": "XBiotech has received FDA authorization to begin its V-SPINE trial, which will enroll 150 patients with active axial spondyloarthritis to evaluate the efficacy of Vilamakitug (XP2001 or Natrunix). This IgG4 monoclonal antibody targets IL-1\u03b1, aiming to reduce structural damage and", "url": "https://intellectia.ai/news/stock/xbiotech-receives-authorization-for-vspine-trial", "source_name": "Intellectia AI", "published_at": "2026-06-16T05:39:22", "published_display": "16 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondyloarthritis", "summary": "The FDA has cleared XBiotech Inc. to proceed with its Phase II V-SPINE trial of vilamakitug for active axial spondyloarthritis, marking a restart of the company's rheumatology program. This regulatory approval allows XBiotech to begin enrolling patients in the U.S. for the random", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xbiotech-inc-stock-us9840001002-fda-clears-phase-ii-v-spine-trial-for/69547716", "source_name": "AD HOC NEWS", "published_at": "2026-06-16T01:09:26", "published_display": "16 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech clears FDA review for axial spondyloarthritis study", "summary": "XBiotech Inc. has announced that its Investigational New Drug application for the V-SPINE study successfully completed the FDA's 30-day review period without a clinical hold, allowing the company to proceed with patient enrollment in the U.S. for its Phase II axial spondyloarthri", "url": "https://www.investing.com/news/company-news/xbiotech-clears-fda-review-for-axial-spondyloarthritis-study-93CH-4742224", "source_name": "Investing.com", "published_at": "2026-06-15T13:09:26", "published_display": "15 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA review lets XBiotech resume rheumatology with axial spondyloarthritis trial", "summary": "XBiotech (NASDAQ: XBIT) announced FDA clearance for its Phase II V-SPINE trial of vilamakitug for active axial spondyloarthritis, allowing U.S. patient enrollment. The IND application completed its 30-day review without clinical hold, marking the resumption of XBiotech\u2019s rheumato", "url": "https://www.stocktitan.net/news/XBIT/x-biotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-erzx8m4p9w29.html", "source_name": "Stock Titan", "published_at": "2026-06-15T13:09:26", "published_display": "15 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIT - XBiotech Inc Dividends", "summary": "This article provides a detailed financial overview of XBiotech Inc (XBIT), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists dividend information such as the ex-dividend date (July 15, 2021) and performance metrics ", "url": "https://finviz.com/stock?t=XBIT&ta=1&p=d&ty=dv", "source_name": "Finviz", "published_at": "2026-06-03T20:41:05", "published_display": "03 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update", "summary": "XBiotech Inc. (XBIT) shares traded sideways on Nasdaq on June 2, 2026, as the Austin-based biotech company awaits its next earnings update. With no new company filings or press releases on the day, investor expectations are still shaped by results reported in late 2024. The compa", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/xbiotech-inc-stock-us9840001002-shares-little-changed-as-investors/69471161", "source_name": "Ad Hoc News", "published_at": "2026-06-02T13:39:03", "published_display": "02 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech: Q1 Earnings Snapshot", "summary": "XBiotech Inc. (XBIT) reported a first-quarter loss of $5.5 million, translating to 18 cents per share. This financial snapshot was generated using data from Zacks Investment Research.", "url": "https://www.barchart.com/story/news/1939735/xbiotech-q1-earnings-snapshot", "source_name": "Barchart.com", "published_at": "2026-05-29T06:41:20", "published_display": "29 May 2026 06:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbiotech (XBIT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBOdkRCMEs4YTdnTm8yeFNNeG15NmltZU5hQjROTXl3T0tSMnBINUMySTlDUW4zZnNBTG8yUUQ5S3lLajhuRXNGTW9VcWliNzE1Zy1j?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T23:03:39+00:00", "published_display": "24 Apr 2025 23:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "First look: XBiotech to expand Austin HQ with more offices, state-of-the-art R&D facility", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPMkkycTBWZFdtVk1KREhCZUtaSXNDU3pTWDZoRlQ3bEg1bnZVWXpaT0E2Q1ZUMVBZWXBXa21sWkRlWkdEdWpqSVpUZzllbEcyNjVscFd1Y1J3ZjNZR1VfSlc0SlFybUZBLUpSVnJRZF9uRWE3c3hGeVdMUGNPQloxaTItaEx4VS1qS093ZjlWNXp3Vkl4dDBmLUJR?oc=5", "source_name": "The Business Journals", "published_at": "2020-12-23T08:00:00+00:00", "published_display": "23 Dec 2020 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbiotech Stock Price Forecast. Should You Buy XBIT?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE9CbDR0UnNTZUtlR1R5N0F6T2tuUUxuNlN1SXN0eVFKdkNac0RxSTJSMERuUEVIdlhYTVhnN3g4MXN5a21HS2RZQQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-02T17:57:50+00:00", "published_display": "02 Dec 2020 17:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Janssen to Acquire Investigational Bermekimab from XBiotech", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQbnJZM3pMelp6endYNzFpMDl0RnVvTDRZQmVwQTZyMkZIeTVQMWRac2ptUzc1ZHRnTlFDYjV4OHBhUS1WTXpzZ2ZNSW5aZW5ydDNueUNrYnZORjdRa2NLXzNfbDg2bG43Vk80SFB0ZUdzODc0NkpHaVRyWnJDVDVzTFUtb1pkcWFPQ1ZYRHBnM1huVmhoN3RVVXVpblE4RTNubUhwLVctTTZxa1FBaHc0SjJYa2lNdw?oc=5", "source_name": "PR Newswire", "published_at": "2019-12-07T08:00:00+00:00", "published_display": "07 Dec 2019 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Technical Analysis of XBiotech Inc. (NASDAQ:XBIT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE4zU1RVbGkyZmNteE9telYzN3E4ZkV3Q1Q2Y2JBN1F5UFZfRHFBSjI3dzJGNjdFNFZ4TEtUWk9ZWWJwZWNOVnQwQXJIaEl5WTk3SmtiSWxVYXNsUUgwTlJSeVZnWmdPYk1nenM0?oc=5", "source_name": "TradingView", "published_at": "2018-02-09T18:07:45+00:00", "published_display": "09 Feb 2018 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIT Stock Price and Chart \u2014 NASDAQ:XBIT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5jaExkNWJjTzU0OEhNOTNhWWFlTEdkRXlKN0V0bHR0eUg2bC1vbDdSZ2drcU1HM2IwTmRDaFpQUldTLXpKNFVVNzgySGtyZTZsRGlWbi1iNklwR0xn?oc=5", "source_name": "TradingView", "published_at": "2017-07-21T05:24:49+00:00", "published_display": "21 Jul 2017 05:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBiotech (XBIT) Stock Price, News & Analysis $XBIT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1wcXZqOWgzTFZYSVBGYVJmbm8zUXZWY0YwUjNlSWNsRkF2SnNEcFJNRU5aTUs3Z3dYZ2d0a0hKaUp6RnhxaU9ONjBpTEFxNkpnTy1fV1dNYURJUQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-14T04:32:11+00:00", "published_display": "14 Aug 2016 04:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIT: XBiotech Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTFBNZ1dBZkxSRE5jMmhab05oNHBDdUR2UlBrcGxUZ0o1U3B3VUh2QTI5N1VkTjhNS3l3aTh2T0tTVC1FZHk0Zy1jVlJR?oc=5", "source_name": "Stocktwits", "published_at": "2015-11-24T03:16:14+00:00", "published_display": "24 Nov 2015 03:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 46, "sentiment_summary": {"positive": 7, "negative": 6, "neutral": 33, "score": 52, "total": 46, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 12.1, "count": 22}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 7, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 2.29, "latest_week": "2026-07-10", "one_week_move": -0.4, "four_week_move": -2.1, "twelve_week_move": -6.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.033405, "market_dynamics_buy_signal": false, "relative_strength": -22.867426, "fair_value_gap": -47.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.5307, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.4% over one week, -2.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "TradingKey", "count": 8}, {"label": "Market source", "count": 6}, {"label": "dars.gov.et", "count": 3}, {"label": "Ad Hoc News", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "The Manila Times", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 22}, {"label": "Earnings", "count": 14}, {"label": "Regulatory and legal", "count": 4}, {"label": "Balance sheet", "count": 2}, {"label": "Capital return", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.4% over one week, -2.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading Continues - IPO Entry Watch"}], "updated_at": "2026-07-18T01:52:00.271187+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}